• Gislaine Silveira OlmEmail author


The World Health Organization estimates that more than 400 million people are infected with either hepatitis B virus or hepatitis C virus while approximately 150 million have chronic hepatitis C. Viral hepatitis, specifically hepatitis B and hepatitis C, not only causes liver disease but also can present with extrahepatic manifestations, including cutaneous lesions. Among all extrahepatic manifestations of liver diseases, cutaneous manifestations are the most common. In addition, they are easily recognizable and may provide the first clues of liver disease. Serum sickness and polyarteritis nodosa are the main cutaneous manifestations related to hepatitis B virus infection. Cutaneous manifestations related to hepatitis C virus infection include mixed cryoglobulinemia, porphyria cutanea tarda, and lichen planus. In addition, the appearance of adverse cutaneous reactions both local and diffuse is frequent during the treatment of hepatitis C virus infection.


Hepatitis B Hepatitis C Cutaneous manifestation Serum sickness-like Polyarteritis nodosa Mixed cryoglobulinemia Porphyria cutanea tarda Lichen planus Cutaneous reaction 




Characterized by the presence of cryoglobulins in the serum. This may result in a clinical syndrome of systemic inflammation caused by cryoglobulin-containing immune complexes.


Yellowish discoloration of the skin, white of the eyes, and mucous membranes caused by deposition of bile salts in the tissues.


Inflammation of the liver, caused by a virus or a toxin and characterized by jaundice, liver enlargement, and fever.

Polyarteritis nodosa 

Systemic necrotizing vasculitis that predominantly affects medium-sized muscular arteries and often involves small muscular arteries, resulting in secondary tissue ischemia.


Group of diseases in which there is abnormal metabolism of the blood pigment hemoglobin.


  1. 1.
    World Health Organization. 2016. Accessed 20 Feb 2016.
  2. 2.
    Akhter A, Said A. Cutaneous manifestation of viral hepatitis. Curr Infect Dis Rep. 2015;17:1–8.CrossRefGoogle Scholar
  3. 3.
    Ghosn S, Kibbi AG. Cutaneous manifestation of liver diseases. Clin Dermatol. 2008;26:274–82.CrossRefPubMedGoogle Scholar
  4. 4.
    World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015. Accessed 20 Feb 2016.Google Scholar
  5. 5.
    Bhat M, Ghali P, Deschenes M, Wong P. Prevention and management of chronic hepatitis B. Int J Prev Med. 2014;5(3):S200–7.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.CrossRefPubMedGoogle Scholar
  7. 7.
    McElgunn PS. Dermatologic manifestation of hepatitis B virus infection. Am J Dermatol. 1983;8(4):539–47.CrossRefGoogle Scholar
  8. 8.
    Han SH. Extrahepatic manifestation of chronic hepatitis B. Clin Liver Dis. 2004;8:403–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Jones AM, Warken K, Tyring SK. The cutaneous manifestation of viral hepatitis. Dermatol Clin. 2002;20:233–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Nishida N, Kudo M. Clinical features of vascular disorders associated with chronic hepatitis virus infection. Dig Dis. 2014;32:786–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, Cid MC. Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014;48–49:84–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Gianotti F. Rilievi di una particolare casistica tossinfettiva caraterizzata de eruzione eritemato-infiltrativa desquamativa a foccolai lenticolari, a sede elettiva acroesposta. G Ital Dermatol. 1955;96:678–9.Google Scholar
  14. 14.
    Crosti A, Gianotti F. Dermatosi infantile eruttiva acroesposta di probabile origine virosica. Minerva Dermatol. 1956;31(Suppl):483.Google Scholar
  15. 15.
    De Gaspari G, Bardare M, Costantino D. Au antigen in Crosti-Gianotti acrodermatitis. Lancet. 1970;1:1116–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Ishimaru Y, Ishimaru H, Toda G, Baba K, Mayumi M. An epidemic of infantile papular acrodermatitis (Gianotti’s disease) in Japan associated with hepatitis-B surface antigensubtype ayw. Lancet. 1976;1:707–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Brandt O, Abeck D, Gianotti, Burgdorf W. Gianotti-Crosti syndrome. J Am Acad Dermatol. 2006;54(1):136–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Rebora A. Skin diseases associated with hepatitis C virus: facts and controversies. Clin Dermatol. 2010;28:489–96.CrossRefPubMedGoogle Scholar
  19. 19.
    Ko HM, Hernandez-Prera JC, Zhu H, Dikman SH, Sidhu HK, Ward SC, et al. Clin Dev Immunol. 2012;2012:740138.Google Scholar
  20. 20.
    Gargovich S, Gargovich M, Capizzi R, Gasbarrini A, Zocco MA. Cutaneous manifestation of hepatitis C in the era of new antiviral agents. World J Hepatol. 2015;7(27):2740–8.CrossRefGoogle Scholar
  21. 21.
    Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: what is the current state-what come’s nex? World J Hepatol. 2016;8(3):139–47.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis-C associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology. 2007;46:1234–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Luckács J, Schliemann S, Elsner P. Lichen planus and lichenoid reactions as a systemic disease. Clin Dermatol. 2015;33:512–9.CrossRefGoogle Scholar
  26. 26.
    Mokni M, Rybojad M, Puppin D Jr, et al. Lichen planus and hepatitis C virus. J Am Acad Dermatol. 1991;24:792.CrossRefPubMedGoogle Scholar
  27. 27.
    Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010;16:601–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Kanada KN, Schupp CW, Armstrong AW. Association between psoriasis and viral infections in the United States: focusing on hepatitis B, hepatitis C and human immunodeficiency virus. J Eur Acad Venereol. 2013;27(10):1312–6.Google Scholar
  29. 29.
    Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology. 2010;220(3):218–22.CrossRefPubMedGoogle Scholar
  30. 30.
    Imafuku S, Nakayama J. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol. 2013;40:428–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Youssef R, Abu-Zeid O, Sayde K, Osman S, Omran D, El Shafei A, et al. Hepatitis C infection in Egyptian psoriatic patients: prevalence and correlation with severity of disease. Iran J Public Health. 2015;44(9):1294–5.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Gabr SA, Berika MY, Alghadir A. Apoptosis and clinical severity in patients with psoriasis and HCV infection. Indian J Dermatol. 2014;59(3):230–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Suzuki K, Tamano M, Katayama Y, Kuniyoshi T, Kagawa K, Takada H, et al. Study of pruritus in chronic hepatitis C patients. World J Gastroenterol. 2014;20(47):17877–82.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Tabibian JH, Gersteenblith MR, Tedford RJ, Junkins-Hopkins JM, Abuav R. Necrolytic acral erythema as a cutaneous marker of hepatitis C: report of two cases and review. Dig Dis Sci. 2010;55:2735–43.CrossRefPubMedGoogle Scholar
  35. 35.
    Khanna VJ, Shieh S, Benjamin J, Somach S, Zaim MT, Dorner W, et al. Necrolytic acral erythema associated with hepatitis C effective treatment with interferon alfa and zinc. Arch Dermatol. 2000;136:755–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Raphael BA, Dorey-Stein ZL, Lott J, Amorosa V, Re VL, Kovarik C. Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C vírus infection. J Am Acad Dermatol. 2011;67(5):962–8.CrossRefGoogle Scholar
  37. 37.
    Abdallah MA, Hull C, Horn TD. Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. Arch Dermatol. 2005;141:85.CrossRefPubMedGoogle Scholar
  38. 38.
    Abdallah MA, Ghozzi MY, Monib HA, Hafez AM, Hiatt KM, Smoller BR, et al. Necrolytic acral erythema: a cutaneous sign of hepatitis C virus infection. J Am Acad Dermatol. 2005;53(2):247–51.CrossRefPubMedGoogle Scholar
  39. 39.
    Patrk I, Morovic M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology. 2014;228:42–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Federico A, Sgambato D, Cotticelli G, Gravina AG, Dallio M, Beneduce F, et al. Skin adverse events during dual and triple therapy for HCV-related cirrhosis. Hepat Mon. 2014;14(3):1–3.CrossRefGoogle Scholar
  41. 41.
    Falcão EMM, Trope BM, Godinho MM, Carneiro LH, Araujo-Neto JM, Nogueira CAV, et al. Cutaneous eruption due to telaprevir. Case Rep Dermatol. 2015;7:253–62.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Montecinos MT, Carrilo JM, Rius MV, Marsol B, PLa AP, Cunill RM, et al. Drug eruptions induced by telaprevir in patients with chronic hepatitis C vírus genotype 1 infection: a prospective study. Actas Dermosifiliogr. 2015;106(3):219–25.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  1. 1.Mãe de Deus, DermatologyPorto AlegreBrazil

Personalised recommendations